WO2006069246A2 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides - Google Patents
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Download PDFInfo
- Publication number
- WO2006069246A2 WO2006069246A2 PCT/US2005/046618 US2005046618W WO2006069246A2 WO 2006069246 A2 WO2006069246 A2 WO 2006069246A2 US 2005046618 W US2005046618 W US 2005046618W WO 2006069246 A2 WO2006069246 A2 WO 2006069246A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkylene
- group
- amino acid
- alkyl
- Prior art date
Links
- 0 CNNC*** Chemical compound CNNC*** 0.000 description 31
- GBRLQAWXNMLSLK-UHFFFAOYSA-N NC(Cc1ccc(CCC2OCCO2)cc1)C(O)=O Chemical compound NC(Cc1ccc(CCC2OCCO2)cc1)C(O)=O GBRLQAWXNMLSLK-UHFFFAOYSA-N 0.000 description 2
- YVBRFBNRDRVUAF-UHFFFAOYSA-N CC(C)(C)OC(NC(Cc(cc1)ccc1C(C)=O)C(O)=O)=O Chemical compound CC(C)(C)OC(NC(Cc(cc1)ccc1C(C)=O)C(O)=O)=O YVBRFBNRDRVUAF-UHFFFAOYSA-N 0.000 description 1
- SPRJGSCBADVFFP-LICLKQGHSA-N CC(C)(C)OC(NC(Cc1ccc(/C=N/O)cc1)C(OC)=O)=O Chemical compound CC(C)(C)OC(NC(Cc1ccc(/C=N/O)cc1)C(OC)=O)=O SPRJGSCBADVFFP-LICLKQGHSA-N 0.000 description 1
- DZADWDGWLWJMNR-UHFFFAOYSA-N CN[N](C)(C)C1CC1 Chemical compound CN[N](C)(C)C1CC1 DZADWDGWLWJMNR-UHFFFAOYSA-N 0.000 description 1
- BKNCSPZEGXUNTP-UHFFFAOYSA-N COC(Oc(cc1)ccc1[N+]([O-])=O)=O Chemical compound COC(Oc(cc1)ccc1[N+]([O-])=O)=O BKNCSPZEGXUNTP-UHFFFAOYSA-N 0.000 description 1
- OZBYPWSRIYNGHY-UHFFFAOYSA-N NC(Cc(cc1)ccc1C(CC1OCCO1)=O)C(O)=O Chemical compound NC(Cc(cc1)ccc1C(CC1OCCO1)=O)C(O)=O OZBYPWSRIYNGHY-UHFFFAOYSA-N 0.000 description 1
- UJBCNLOGGSUZNU-UHFFFAOYSA-N NC(Cc(cc1)ccc1SCC1OCCO1)C(O)=O Chemical compound NC(Cc(cc1)ccc1SCC1OCCO1)C(O)=O UJBCNLOGGSUZNU-UHFFFAOYSA-N 0.000 description 1
- FKKQDMDPEHRMGK-UHFFFAOYSA-N NC(Cc1ccc(CC2OCCO2)cc1)C(O)=O Chemical compound NC(Cc1ccc(CC2OCCO2)cc1)C(O)=O FKKQDMDPEHRMGK-UHFFFAOYSA-N 0.000 description 1
- WETLKXFMOJSTDH-UHFFFAOYSA-N NC(Cc1ccc(CCCCC2OCCO2)cc1)C(O)=O Chemical compound NC(Cc1ccc(CCCCC2OCCO2)cc1)C(O)=O WETLKXFMOJSTDH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007548475A JP5425398B2 (ja) | 2004-12-22 | 2005-12-21 | 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用 |
MX2007007590A MX2007007590A (es) | 2004-12-22 | 2005-12-21 | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
GB0713066A GB2438982A (en) | 2004-12-22 | 2005-12-21 | Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides |
EP11177567.2A EP2399893B1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
KR1020077016540A KR101423769B1 (ko) | 2004-12-22 | 2005-12-21 | 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 그와관련된 방법 및 그의 용도 |
AU2005319125A AU2005319125A1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
BRPI0516385-4A BRPI0516385B1 (pt) | 2004-12-22 | 2005-12-21 | Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo |
NZ555308A NZ555308A (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
CA2590590A CA2590590C (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
EP05855215.9A EP1828224B1 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
DK05855215.9T DK1828224T3 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
IL183346A IL183346A (en) | 2004-12-22 | 2007-05-21 | Unnatural amino acids containing an oxide group |
HK08102427.1A HK1111702A1 (zh) | 2004-12-22 | 2008-03-04 | 含有非天然氨基酸及多肽的組合物及其所涉及的方法和用途 |
AU2010226982A AU2010226982B2 (en) | 2004-12-22 | 2010-10-06 | Compositions containing, methods involving and uses of non-natural amino acids and polypeptides |
IL220740A IL220740A (en) | 2004-12-22 | 2012-07-03 | Unnatural amino acids containing oxide group |
IL227753A IL227753A (en) | 2004-12-22 | 2013-08-01 | Antibody or residual antibody residues |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63841804P | 2004-12-22 | 2004-12-22 | |
US63919504P | 2004-12-22 | 2004-12-22 | |
US63852704P | 2004-12-22 | 2004-12-22 | |
US60/639,195 | 2004-12-22 | ||
US60/638,527 | 2004-12-22 | ||
US60/638,418 | 2004-12-22 | ||
US69621005P | 2005-07-01 | 2005-07-01 | |
US69630205P | 2005-07-01 | 2005-07-01 | |
US69606805P | 2005-07-01 | 2005-07-01 | |
US60/696,068 | 2005-07-01 | ||
US60/696,302 | 2005-07-01 | ||
US60/696,210 | 2005-07-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006069246A2 true WO2006069246A2 (en) | 2006-06-29 |
WO2006069246A9 WO2006069246A9 (en) | 2006-08-31 |
WO2006069246A3 WO2006069246A3 (en) | 2008-09-25 |
Family
ID=36602327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/046618 WO2006069246A2 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
Country Status (16)
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
US7468458B2 (en) | 2005-11-08 | 2008-12-23 | Amerx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
JP2010523084A (ja) * | 2007-03-30 | 2010-07-15 | アンブルックス,インコーポレイテッド | 修飾fgf−21ポリペプチド |
WO2011001052A1 (fr) | 2009-06-29 | 2011-01-06 | Sanofi-Aventis | Nouveaux conjugues, leur preparation et leur application en therapeutique |
WO2011023883A1 (fr) | 2009-08-25 | 2011-03-03 | Sanofi-Aventis | Conjugues de dimeres de pyrrolo [1, 4 ] benzodiazepine en tant qu' anticancereux |
WO2011039721A1 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
US7928163B2 (en) | 2004-12-22 | 2011-04-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
AU2006326404B2 (en) * | 2005-12-14 | 2011-11-03 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
WO2012014147A1 (en) | 2010-07-26 | 2012-02-02 | Sanofi | Anticancer derivatives, preparation thereof and therapeutic use thereof |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US8518666B2 (en) | 2006-03-03 | 2013-08-27 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
JP2013199466A (ja) * | 2012-02-24 | 2013-10-03 | Fujifilm Corp | リコピン含有組成物 |
WO2013185117A1 (en) * | 2012-06-07 | 2013-12-12 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
WO2013192360A1 (en) * | 2012-06-19 | 2013-12-27 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
WO2014004639A1 (en) * | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014114207A1 (zh) | 2013-01-23 | 2014-07-31 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
EP2819702A4 (en) * | 2012-02-29 | 2015-05-20 | Ambrx Inc | NOVEL PRODRUGS WITH MOLECULE COMPOSITIONS AND ITS USES |
US9133457B2 (en) | 2004-05-17 | 2015-09-15 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
WO2016065326A2 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
US9682934B2 (en) | 2012-08-31 | 2017-06-20 | Sutro Biopharma, Inc. | Modified amino acids |
US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9879249B2 (en) | 2009-02-17 | 2018-01-30 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
EP3279660A4 (en) * | 2015-03-31 | 2018-09-05 | Eiken Kagaku Kabushiki Kaisha | Preservative solution for heme protein, and method for stabilizing heme protein |
US10183998B2 (en) | 2011-01-14 | 2019-01-22 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
US10232051B2 (en) | 2015-07-15 | 2019-03-19 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
WO2019185705A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
WO2019185706A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
WO2021000067A1 (zh) | 2019-06-29 | 2021-01-07 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
EP3888691A1 (en) | 2016-11-14 | 2021-10-06 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
WO2021245130A1 (en) | 2020-06-03 | 2021-12-09 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
WO2023281483A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified tnf-antibodies and uses thereof |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
WO2023281479A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
WO2023281481A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics | Antibody conjugates and manufacture thereof |
US11708413B2 (en) | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
WO2023161854A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
WO2023161857A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US20220144872A1 (en) * | 2003-02-19 | 2022-05-12 | Panion & Bf Biotech Inc. | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same |
US20080076700A1 (en) * | 2004-10-18 | 2008-03-27 | Novo Nordisk A/S | Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone |
JP5312799B2 (ja) * | 2005-01-25 | 2013-10-09 | ファイザー アイルランド ファーマシューティカルズ | 収集精密ろ過における剪断保護剤 |
CA2630415A1 (en) * | 2005-10-20 | 2007-04-26 | The Scripps Research Institute | Fc labeling for immunostaining and immunotargeting |
RS52459B (en) | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies Inc. | STABILIZED GLUCOCEREBROSIDASE COMPOSITIONS |
US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
US8114844B2 (en) * | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
US7964181B2 (en) * | 2006-03-30 | 2011-06-21 | Palatin Technologies, Inc. | Amino acid surrogates for peptidic constructs |
WO2008049034A1 (en) * | 2006-10-17 | 2008-04-24 | Zymera, Inc. | System for assays of aminotranferase |
US20100143326A1 (en) * | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
AU2008335778B2 (en) | 2007-12-11 | 2014-04-10 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris |
JP5514736B2 (ja) | 2008-01-11 | 2014-06-04 | セリナ・セラピユーテイツクス・インコーポレーテツド | ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物 |
US8101706B2 (en) * | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
JP5702150B2 (ja) * | 2008-02-08 | 2015-04-15 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾されているレプチンポリペプチドおよびそれらの使用 |
DE102008002209A1 (de) * | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Aufreinigung von Erythropoietin |
CN102307905B (zh) * | 2008-12-10 | 2015-11-25 | 斯克利普斯研究院 | 利用化学反应性非天然氨基酸产生载体-肽偶联物 |
US20090197339A1 (en) * | 2008-12-10 | 2009-08-06 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris |
EP2406276A4 (en) * | 2009-03-13 | 2012-12-05 | Aerovance Inc | METHOD OF RENATURING RECOMBINANT PROTEINS |
DE102009015347A1 (de) * | 2009-03-27 | 2010-09-30 | Man Nutzfahrzeuge Aktiengesellschaft | Dieselkraftstoff auf Ethanol-Basis |
ES2668079T3 (es) | 2009-07-28 | 2018-05-16 | Shire Human Genetic Therapies | Composiciones y métodos para tratar la enfermedad de Gaucher |
WO2011044255A1 (en) * | 2009-10-06 | 2011-04-14 | The Ohio State University | Pyrrolysine analogs |
US20110160143A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Psoriasis Compositions |
JP6210685B2 (ja) | 2010-01-27 | 2017-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤 |
JP5794558B2 (ja) * | 2010-03-24 | 2015-10-14 | 国立研究開発法人産業技術総合研究所 | 改変された致死遺伝子及び該遺伝子を含むベクター |
CA2865614A1 (en) | 2012-03-02 | 2013-09-06 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type iii gaucher disease |
CA2871160C (en) | 2012-05-10 | 2023-03-14 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
GB201211353D0 (en) | 2012-06-26 | 2012-08-08 | Cm Online Ltd | Interactive video |
JP6574754B2 (ja) | 2013-03-19 | 2019-09-11 | ベイジン シェノゲン ファーマ グループ リミテッド | エストロゲン受容体関連疾患を処置するための抗体及び方法 |
WO2016069726A1 (en) * | 2014-10-28 | 2016-05-06 | President And Fellows Of Harvard College | Methods of making polypeptides with non-standard amino acids using genomically recoded organisms |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
EA039794B1 (ru) | 2014-12-04 | 2022-03-15 | Селджин Корпорейшн | Конъюгаты биомолекул |
KR20240046641A (ko) | 2015-04-17 | 2024-04-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 조율가능한 친화성을 갖는 면역조절 단백질 |
US11884612B2 (en) | 2016-03-16 | 2024-01-30 | The Regents Of The University Of California | Covalent peptide binders |
AU2018225163A1 (en) | 2017-02-22 | 2019-09-19 | Bioincept, Llc | Peptides and methods of treating dystrophy-related disorders using the same |
WO2018200381A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
BR112020000115A2 (pt) * | 2017-07-05 | 2020-07-07 | Biocells (Beijing) Biotech Co., Ltd. | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos |
WO2019018447A2 (en) | 2017-07-17 | 2019-01-24 | Bioincept, Llc | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATION OF ORGAN FUNCTION |
EP3761972A4 (en) * | 2018-03-08 | 2021-12-15 | The Regents of the University of California | BIOREACTIVE COMPOSITIONS AND METHOD OF USING THEREOF |
CN108538399A (zh) * | 2018-03-22 | 2018-09-14 | 复旦大学 | 一种磁共振肝癌疗效评估方法和系统 |
CN110760306B (zh) * | 2018-07-27 | 2021-11-23 | Tcl科技集团股份有限公司 | 一种量子点的提纯方法 |
MX2021002301A (es) | 2018-08-28 | 2021-04-28 | Ambrx Inc | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. |
JP2021536263A (ja) * | 2018-09-07 | 2021-12-27 | メディミューン,エルエルシー | 細胞選択の方法 |
CA3130693A1 (en) | 2019-02-19 | 2020-08-27 | Ultima Genomics, Inc. | Linkers and methods for optical detection and sequencing |
WO2021102624A1 (en) * | 2019-11-25 | 2021-06-03 | Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences | Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx) |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
JPWO2021215428A1 (US20060217532A1-20060928-C00019.png) * | 2020-04-22 | 2021-10-28 | ||
CN112028987B (zh) * | 2020-06-01 | 2021-07-30 | 广东圣赛生物科技有限公司 | 一种结合免疫抑制分子pd-l1的蛋白药物 |
EP4199969A1 (en) * | 2020-08-18 | 2023-06-28 | Ultima Genomics, Inc. | Reagents for labeling biomolecules |
WO2022194078A1 (zh) * | 2021-03-15 | 2022-09-22 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
EP4330214A2 (en) * | 2021-04-28 | 2024-03-06 | The Regents of the University of California | Bioreactive proteins containing unnatural amino acids |
KR102524528B1 (ko) * | 2022-11-24 | 2023-04-21 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드의 제조방법 |
KR102526689B1 (ko) * | 2022-11-24 | 2023-04-28 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드-4를 포함하는 액정수화 화장료 조성물 |
Citations (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
EP0036776A2 (en) | 1980-03-24 | 1981-09-30 | Genentech, Inc. | A method of creating an expression plasmid |
EP0036676A1 (en) | 1978-03-24 | 1981-09-30 | The Regents Of The University Of California | Method of making uniformly sized liposomes and liposomes so made |
EP0052322A2 (de) | 1980-11-10 | 1982-05-26 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0073657A1 (en) | 1981-08-31 | 1983-03-09 | Genentech, Inc. | Preparation of hepatitis B surface antigen in yeast |
EP0088046A2 (de) | 1982-02-17 | 1983-09-07 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4412989A (en) | 1981-06-10 | 1983-11-01 | Ajinomoto Company Incorporated | Oxygen carrier |
US4414148A (en) | 1981-04-15 | 1983-11-08 | Sanofi | Anti-cancer drugs for the treatment of melanomas and method for preparing thereof |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A2 (de) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
EP0121775A1 (en) | 1983-03-09 | 1984-10-17 | Teruhiko Beppu | Novel expression plasmids and their use in the method for expressing prochymosin coding gene in E. coli |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0127839A2 (en) | 1983-05-27 | 1984-12-12 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4512922A (en) | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
EP0142641A2 (de) | 1983-09-26 | 1985-05-29 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
EP0143949A1 (en) | 1983-11-01 | 1985-06-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
EP0155476A1 (en) | 1984-01-31 | 1985-09-25 | Idaho Research Foundation, Inc. | Production of polypeptides in insect cells |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
EP0164556A2 (en) | 1984-05-11 | 1985-12-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid promoter region constructs |
US4569789A (en) | 1984-08-29 | 1986-02-11 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound, use in protein conjugates and drug delivery systems |
EP0188256A2 (en) | 1985-01-14 | 1986-07-23 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
EP0244234A2 (en) | 1986-04-30 | 1987-11-04 | Alko Group Ltd. | Transformation of trichoderma |
US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
WO1988007082A1 (en) | 1987-03-16 | 1988-09-22 | American Biogenetic Sciences, Inc. | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides |
EP0284044A1 (en) | 1987-03-23 | 1988-09-28 | Zymogenetics, Inc. | High level expression in yeast |
WO1989001038A1 (en) | 1987-07-24 | 1989-02-09 | Cetus Corporation | PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM |
WO1989001037A1 (en) | 1987-07-24 | 1989-02-09 | Cetus Corporation | Production of ricin toxins in a baculovirus-insect cell expression system |
US4820352A (en) | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
EP0324274A1 (en) | 1987-12-30 | 1989-07-19 | Chiron Corporation | Improved expression and secretion of heterologous proteins in yeast employing truncated alpha-factor leader sequences |
WO1989006699A1 (en) | 1988-01-13 | 1989-07-27 | Institut Pasteur | Dna probe specific for hemolytic listeria |
EP0329203A1 (en) | 1983-02-22 | 1989-08-23 | Chiron Corporation | Yeast expression systems with vectors having PyK promoters, and synthesis of foreign protein |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
EP0340986A2 (en) | 1988-05-06 | 1989-11-08 | Chiron Corporation | High level expression of proteins in yeast |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
WO1990001556A1 (en) | 1988-08-05 | 1990-02-22 | Mount Sinai School Of Medicine Of The City University Of New York | In vivo infection of live insects with a recombinant baculovirus |
WO1990002186A1 (en) | 1988-08-16 | 1990-03-08 | Polly Roy | Production of bluetongue virus non-structural proteins using a baculovirus expression vector |
WO1990002566A1 (en) | 1988-09-02 | 1990-03-22 | Molecular Engineering Associates, Inc. | Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
WO1990005785A1 (en) | 1988-11-18 | 1990-05-31 | The Regents Of The University Of California | Method for site-specifically incorporating unnatural amino acids into proteins |
WO1990010277A1 (en) | 1989-02-24 | 1990-09-07 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
WO1990010078A1 (en) | 1989-02-23 | 1990-09-07 | University Of Ottawa | Improved baculovirus expression system capable of producing foreign gene proteins at high levels |
WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1990014428A1 (en) | 1989-05-17 | 1990-11-29 | University Of Georgia Research Foundation, Inc. | Improved baculovirus expression vectors |
WO1991000357A1 (fr) | 1989-06-30 | 1991-01-10 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
WO1992001801A1 (fr) | 1990-07-18 | 1992-02-06 | Institut National De La Recherche Agronomique (Inra) | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus |
US5089398A (en) | 1983-02-22 | 1992-02-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid GAPDH promoter region constructs |
WO1992003628A1 (fr) | 1990-08-14 | 1992-03-05 | Jean Arbona | Unite de soins modulaire |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1992016619A1 (en) | 1991-03-19 | 1992-10-01 | Us Army | Expression of influenza nucleoprotein antigens in baculovirus |
WO1993003173A1 (en) | 1991-07-31 | 1993-02-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Improved expression of influenza a m2 protein in baculovirus and uses of m2 protein |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5231178A (en) | 1991-01-16 | 1993-07-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Method for the purification of intact, correctly-folded insulin-like growth factor-1 |
WO1993015189A1 (en) | 1992-01-29 | 1993-08-05 | Consiglio Nazionale Delle Ricerche | A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
WO1994009027A1 (en) | 1992-10-13 | 1994-04-28 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324639A (en) | 1990-09-04 | 1994-06-28 | The Salk Institute Biotechnology/Industrial Assoc, Inc. | Production of insulin-like growth factor-1 in methylotrophic yeast cells |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
WO1994017039A1 (en) | 1993-01-19 | 1994-08-04 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
WO1994018247A1 (en) | 1993-02-02 | 1994-08-18 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
WO1995020672A1 (fr) | 1994-01-31 | 1995-08-03 | Proteine Performance | Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux |
US5468478A (en) | 1987-08-03 | 1995-11-21 | Oxis International, Inc. | Conjugates of superoxide dismutage coupled to high molecular weight polyalkylene glycols |
WO1996006161A1 (en) | 1994-08-24 | 1996-02-29 | Boyce Thompson Institute For Plant Research, Inc. | Establishment of trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
WO1996021469A1 (en) | 1995-01-10 | 1996-07-18 | Shearwater Polymers, Inc. | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
WO1996025496A1 (en) | 1995-02-17 | 1996-08-22 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM |
WO1996029400A1 (fr) | 1995-03-23 | 1996-09-26 | Institut National De La Recherche Agronomique (Inra) | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en ×uvre dudit procede |
US5583023A (en) | 1988-05-31 | 1996-12-10 | Institut National De La Recherche Agronomique | Modified baculovirus, its preparation process and its application as a gene expression vector |
US5605827A (en) | 1993-11-04 | 1997-02-25 | The Ohio State University Research Foundation | Infectious bursal disease virus VP2 fusion protein expressed by baculovirus |
US5629203A (en) | 1990-07-20 | 1997-05-13 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
WO1997026332A1 (en) | 1996-01-17 | 1997-07-24 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5674706A (en) | 1988-05-06 | 1997-10-07 | Chiron Corporation | High level expression of proteins in yeast |
US5753220A (en) | 1994-03-15 | 1998-05-19 | Katakura Industries Co., Ltd. | Cysteine protease gene defective baculovirus, process for its production, and process for the production of economic protein by using the same |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
WO1998026080A1 (en) | 1996-12-13 | 1998-06-18 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
WO1998037208A1 (en) | 1997-02-19 | 1998-08-27 | Chiron S.P.A. | Expression of heterologous proteins |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5843733A (en) | 1986-12-30 | 1998-12-01 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
US5861279A (en) | 1996-01-17 | 1999-01-19 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
WO1999005297A1 (en) | 1997-07-25 | 1999-02-04 | Zeneca Limited | T7 promoter-based expression system |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
WO1999007862A1 (en) | 1997-08-05 | 1999-02-18 | Chiron Corporation | Novel pichia pastoris gene sequences and methods for their use |
WO1999009193A1 (de) | 1997-08-15 | 1999-02-25 | Hepavec Ag Für Gentherapie | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
WO1999010515A1 (en) | 1997-08-21 | 1999-03-04 | University Technologies International, Inc. | Baculovirus artificial chromosomes and methods of use |
US5900461A (en) | 1993-11-12 | 1999-05-04 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
WO1999031257A2 (en) | 1997-12-18 | 1999-06-24 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Protein expression in baculovirus vector expression systems |
WO1999045130A1 (en) | 1998-03-04 | 1999-09-10 | Onyx Pharmaceuticals, Inc. | Baculovirus expression system and method for high throughput expression of genetic material |
US5965393A (en) | 1997-07-01 | 1999-10-12 | National Institute Of Immunology | Method for enhancing foreign gene expression in baculovirus expression vector system |
WO1999051721A1 (en) | 1998-04-03 | 1999-10-14 | Seok Kwon Kang | Novel recombinant baculovirus, construction method thereof and insect pesticidal composition containing the same |
US6001800A (en) | 1994-12-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | Spray dried erythropoietin |
US6013433A (en) | 1991-04-26 | 2000-01-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus |
WO2000020032A1 (en) | 1998-10-06 | 2000-04-13 | Trustees Of Dartmouth College | RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY |
US6096304A (en) | 1995-05-17 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Recombinant baculovirus insecticides |
WO2000055345A2 (en) | 1999-03-17 | 2000-09-21 | Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
WO2000055353A1 (en) | 1999-03-17 | 2000-09-21 | The Board Of Trustees Of The Leland Stanford Junior University | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system |
US6168932B1 (en) | 1998-07-13 | 2001-01-02 | Parker Hughes Institute | Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system |
WO2001005956A2 (en) | 1999-07-15 | 2001-01-25 | Boyce Thompson Institute For Plant Research, Inc. | Sialyation of n-linked glycoproteins in the baculovirus expression vector system |
US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
WO2001027301A2 (en) | 1999-10-15 | 2001-04-19 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
US6245528B1 (en) | 1998-07-28 | 2001-06-12 | Academia Sinica | Latent baculovirus expression system |
WO2001090390A1 (en) | 2000-05-26 | 2001-11-29 | Ark Therapeutics Limited | Use of baculovirus vectors in gene therapy |
US6337191B1 (en) | 1999-03-22 | 2002-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Vitro protein synthesis using glycolytic intermediates as an energy source |
WO2002006305A1 (fr) | 2000-07-17 | 2002-01-24 | Institute Of Immunology Co., Ltd. | Procede permettant de recueillir l'enveloppe virale d'un baculovirus |
US6368825B1 (en) | 1998-08-10 | 2002-04-09 | Academia Sinica | Baculovirus containing minimal CMV promoter |
US20020042097A1 (en) | 2000-05-26 | 2002-04-11 | Tirrell David A. | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
US20020081660A1 (en) | 1999-03-17 | 2002-06-27 | Swartz James R. | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel ATP regeneration system |
WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
WO2002098902A2 (en) | 2001-06-05 | 2002-12-12 | Geneprot, Inc. | Improved native chemical ligation with three or more components |
US6521427B1 (en) | 1997-09-16 | 2003-02-18 | Egea Biosciences, Inc. | Method for the complete chemical synthesis and assembly of genes and genomes |
WO2003042235A2 (en) | 2001-11-14 | 2003-05-22 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
US20030143596A1 (en) | 2001-11-07 | 2003-07-31 | Shearwater Corporation | Branched polymers and their conjugates |
US6608183B1 (en) | 1997-07-14 | 2003-08-19 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US20030208046A1 (en) | 2000-09-08 | 2003-11-06 | Hunter Christie L. | Pseudo native chemical ligation |
WO2004035743A2 (en) | 2002-10-16 | 2004-04-29 | The Scripps Research Institute | Site specific incorporation of keto amino acids into proteins |
US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
US20040198637A1 (en) | 2002-12-22 | 2004-10-07 | The Scripps Research Institute | Protein arrays |
WO2004094593A2 (en) | 2003-04-17 | 2004-11-04 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644281A (en) * | 1899-12-01 | 1900-02-27 | Samuel Crump | Process of drying and varnishing prints. |
US3849576A (en) * | 1964-01-29 | 1974-11-19 | Oreal | Process and cosmetic compositions for the treatment of skin and scalp |
GB1366554A (en) * | 1972-03-06 | 1974-09-11 | Science Union & Cie | Phenylalanine derivatives and a process for their preparation |
US4272432A (en) * | 1974-11-13 | 1981-06-09 | American Home Products Corporation | Claudogenic-interceptive nonapeptide |
ZA783356B (en) * | 1977-07-21 | 1979-06-27 | Merrell Toraude & Co | A-halomethyl amino acid derivatives |
DE3043159C2 (de) * | 1980-11-15 | 1982-12-09 | Degussa Ag, 6000 Frankfurt | Cyclische Acetale des Glutaminsäure-γ-semialdehyds, Verfahren zu deren Herstellung und ihre Verwendung |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
JPS61243018A (ja) * | 1985-04-18 | 1986-10-29 | Taisho Pharmaceut Co Ltd | 真菌症治療剤 |
ES2012739T5 (es) | 1987-11-18 | 2001-12-01 | Chiron Corp | Diagnosticos para nanbv. |
US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
CA2018801C (en) * | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
CA2110543A1 (en) * | 1992-12-09 | 1994-06-10 | David E. Wright | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5464820A (en) * | 1993-06-22 | 1995-11-07 | The University Hospital | Specific inhibitors of tissue kallikrein |
DE4335555A1 (de) * | 1993-10-19 | 1995-04-20 | Basf Ag | Oximether und diese enthaltende Copolymerisate |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
JPH09157578A (ja) * | 1995-12-08 | 1997-06-17 | Daikin Ind Ltd | 含フッ素塗料用材料およびそれを用いた被覆方法 |
US5876916A (en) * | 1996-03-18 | 1999-03-02 | Case Western Reserve University | Pyruvate compounds and methods for use thereof |
IL128229A0 (en) * | 1996-08-02 | 1999-11-30 | Ortho Mcneil Pharm Inc | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
US6399337B1 (en) * | 1997-06-06 | 2002-06-04 | The Governors Of The University Of Alberta | α1,3-fucosyltransferase |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6449281B1 (en) | 1997-09-30 | 2002-09-10 | Intel Corporation | Interface control of communication between a control processor and a digital signal processor |
JPH11140076A (ja) * | 1997-11-04 | 1999-05-25 | Dai Ichi Pure Chem Co Ltd | N−アシル−α−アミノアジピン酸−γ−セミアルデヒドエチレンアセタール |
DE69921102T2 (de) | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
PT1062201E (pt) * | 1998-03-11 | 2005-02-28 | Searle & Co | Derivados halogenados de amidino-aminoacidos uteis como inibidores da sintase do acido nitrico |
AU6059699A (en) * | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
GB9929613D0 (en) * | 1999-12-15 | 2000-02-09 | Koninkl Philips Electronics Nv | Manufacture of semiconductor material and devices using that material |
SE0000055D0 (sv) * | 2000-01-10 | 2000-01-10 | Centaur Pharmaceuticals Inc | Novel process |
WO2002000216A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6608196B2 (en) * | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
DE60228954D1 (en) * | 2001-05-03 | 2008-10-30 | Galileo Lab Inc | Pyruvatderivate |
US20030154058A1 (en) * | 2001-06-11 | 2003-08-14 | Keener Bryan F. | Methods and systems for validating translated geometry |
EP1434576A4 (en) * | 2001-09-13 | 2006-03-29 | Kenneth E Miller | METHOD FOR RELIEVING PAIN |
MXPA04004809A (es) * | 2001-11-20 | 2004-08-11 | Pharmacia Corp | Conjugados de hormona de crecimiento humana modificada quimicamente. |
AU2003300139B2 (en) * | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
KR100940619B1 (ko) * | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
EP1663302B1 (en) * | 2003-09-03 | 2012-06-13 | Alpharma, LLC | Method for vaccination of poultry by bacteriophage lysate |
MX2007007590A (es) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
ATE542920T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
JP4478883B2 (ja) * | 2005-03-25 | 2010-06-09 | ヤマハ株式会社 | 音楽再生装置およびプログラム |
DE102005036719A1 (de) * | 2005-07-28 | 2007-02-01 | Carl Zeiss Industrielle Messtechnik Gmbh | Verfahren zum Korrigieren von Interpolationsfehlern einer Maschine, insbesondere eines Koordinatenmessgerätes |
CN101400646A (zh) | 2005-11-08 | 2009-04-01 | Ambrx公司 | 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂 |
CN105384807A (zh) | 2005-12-14 | 2016-03-09 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
AU2006332809A1 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US7760037B2 (en) * | 2007-03-28 | 2010-07-20 | Intel Corporation | Process, voltage, and temperature compensated clock generator |
US20090113333A1 (en) | 2007-10-26 | 2009-04-30 | Palm, Inc. | Extendable Toolbar for Navigation and Execution of Operational Functions |
-
2005
- 2005-12-21 MX MX2007007590A patent/MX2007007590A/es active IP Right Grant
- 2005-12-21 US US11/313,956 patent/US7385028B2/en active Active
- 2005-12-21 KR KR1020077016540A patent/KR101423769B1/ko active IP Right Grant
- 2005-12-21 SG SG200908678-6A patent/SG158186A1/en unknown
- 2005-12-21 WO PCT/US2005/046618 patent/WO2006069246A2/en active Application Filing
- 2005-12-21 CA CA2927595A patent/CA2927595C/en active Active
- 2005-12-21 NZ NZ555308A patent/NZ555308A/en unknown
- 2005-12-21 BR BRPI0516385-4A patent/BRPI0516385B1/pt active IP Right Grant
- 2005-12-21 EP EP11177567.2A patent/EP2399893B1/en active Active
- 2005-12-21 CN CN201510093838.4A patent/CN104803865A/zh active Pending
- 2005-12-21 EP EP05855215.9A patent/EP1828224B1/en active Active
- 2005-12-21 SG SG200908440-1A patent/SG158149A1/en unknown
- 2005-12-21 GB GB0713066A patent/GB2438982A/en not_active Withdrawn
- 2005-12-21 CA CA2590590A patent/CA2590590C/en active Active
- 2005-12-21 US US11/313,306 patent/US7332571B2/en active Active
- 2005-12-21 JP JP2007548475A patent/JP5425398B2/ja active Active
- 2005-12-21 AU AU2005319125A patent/AU2005319125A1/en not_active Abandoned
- 2005-12-21 DK DK05855215.9T patent/DK1828224T3/en active
- 2005-12-21 US US11/313,305 patent/US7638491B2/en active Active
- 2005-12-21 DK DK11177567.2T patent/DK2399893T3/en active
- 2005-12-21 SG SG200908439-3A patent/SG158148A1/en unknown
- 2005-12-21 CA CA3005835A patent/CA3005835C/en active Active
-
2007
- 2007-05-21 IL IL183346A patent/IL183346A/en active IP Right Grant
- 2007-10-16 US US11/873,347 patent/US7928163B2/en active Active
- 2007-10-17 US US11/874,094 patent/US20080177038A1/en not_active Abandoned
- 2007-10-17 US US11/874,060 patent/US7696312B2/en active Active
- 2007-10-18 US US11/874,486 patent/US20080213840A1/en not_active Abandoned
- 2007-10-26 US US11/925,699 patent/US20080268519A1/en not_active Abandoned
- 2007-10-26 US US11/925,662 patent/US20080268518A1/en not_active Abandoned
- 2007-10-26 US US11/925,743 patent/US20090111147A1/en not_active Abandoned
- 2007-12-07 US US11/952,960 patent/US8008456B2/en active Active
- 2007-12-07 US US11/952,975 patent/US8048988B2/en active Active
-
2008
- 2008-02-06 US US12/027,130 patent/US8263740B2/en active Active
- 2008-03-04 HK HK08102427.1A patent/HK1111702A1/zh unknown
-
2009
- 2009-11-05 US US12/613,423 patent/US8367612B2/en active Active
-
2010
- 2010-10-06 AU AU2010226982A patent/AU2010226982B2/en active Active
-
2011
- 2011-01-13 US US13/006,335 patent/US8809511B2/en active Active
- 2011-01-13 US US13/006,361 patent/US8791231B2/en active Active
- 2011-01-13 US US13/006,350 patent/US8859802B2/en active Active
- 2011-07-07 US US13/178,189 patent/US8476411B2/en active Active
-
2012
- 2012-06-20 US US13/528,723 patent/US8846876B2/en active Active
- 2012-07-03 IL IL220740A patent/IL220740A/en active IP Right Grant
-
2013
- 2013-08-01 IL IL227753A patent/IL227753A/en active IP Right Grant
-
2014
- 2014-05-29 US US14/290,797 patent/US9637441B2/en active Active
Patent Citations (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0036676A1 (en) | 1978-03-24 | 1981-09-30 | The Regents Of The University Of California | Method of making uniformly sized liposomes and liposomes so made |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
EP0036776A2 (en) | 1980-03-24 | 1981-09-30 | Genentech, Inc. | A method of creating an expression plasmid |
EP0052322A2 (de) | 1980-11-10 | 1982-05-26 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
US4414148A (en) | 1981-04-15 | 1983-11-08 | Sanofi | Anti-cancer drugs for the treatment of melanomas and method for preparing thereof |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4412989A (en) | 1981-06-10 | 1983-11-01 | Ajinomoto Company Incorporated | Oxygen carrier |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0073657A1 (en) | 1981-08-31 | 1983-03-09 | Genentech, Inc. | Preparation of hepatitis B surface antigen in yeast |
EP0088046A2 (de) | 1982-02-17 | 1983-09-07 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A2 (de) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4512922A (en) | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4820352A (en) | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
EP0732403A1 (en) | 1983-02-22 | 1996-09-18 | Chiron Corporation | Yeast expression systems with vectors having GAPDH promoters, and synthesis of HBsAg |
USRE35749E (en) | 1983-02-22 | 1998-03-17 | Chiron Corporation | Constructs of glyceraldehyde-3-phosphate dehydrogenase promoter and methods for expressing genes using said constructs |
US5089398A (en) | 1983-02-22 | 1992-02-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid GAPDH promoter region constructs |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
EP0329203A1 (en) | 1983-02-22 | 1989-08-23 | Chiron Corporation | Yeast expression systems with vectors having PyK promoters, and synthesis of foreign protein |
EP0121775A1 (en) | 1983-03-09 | 1984-10-17 | Teruhiko Beppu | Novel expression plasmids and their use in the method for expressing prochymosin coding gene in E. coli |
EP0127839A2 (en) | 1983-05-27 | 1984-12-12 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
EP0142641A2 (de) | 1983-09-26 | 1985-05-29 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
EP0143949A1 (en) | 1983-11-01 | 1985-06-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
EP0155476A1 (en) | 1984-01-31 | 1985-09-25 | Idaho Research Foundation, Inc. | Production of polypeptides in insect cells |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
EP0480480A2 (en) | 1984-05-11 | 1992-04-15 | Chiron Corporation | Enhanced yeast transcription employing hybrid promoter region constructs |
EP0164556A2 (en) | 1984-05-11 | 1985-12-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid promoter region constructs |
US4569789A (en) | 1984-08-29 | 1986-02-11 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound, use in protein conjugates and drug delivery systems |
US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
EP0188256A2 (en) | 1985-01-14 | 1986-07-23 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
EP0244234A2 (en) | 1986-04-30 | 1987-11-04 | Alko Group Ltd. | Transformation of trichoderma |
US5843733A (en) | 1986-12-30 | 1998-12-01 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
US5891676A (en) | 1986-12-30 | 1999-04-06 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
WO1988007082A1 (en) | 1987-03-16 | 1988-09-22 | American Biogenetic Sciences, Inc. | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides |
EP0284044A1 (en) | 1987-03-23 | 1988-09-28 | Zymogenetics, Inc. | High level expression in yeast |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
WO1989001037A1 (en) | 1987-07-24 | 1989-02-09 | Cetus Corporation | Production of ricin toxins in a baculovirus-insect cell expression system |
WO1989001038A1 (en) | 1987-07-24 | 1989-02-09 | Cetus Corporation | PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM |
US5468478A (en) | 1987-08-03 | 1995-11-21 | Oxis International, Inc. | Conjugates of superoxide dismutage coupled to high molecular weight polyalkylene glycols |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
USRE37343E1 (en) | 1987-12-30 | 2001-08-28 | Chiron Corporation | Expression and secretion of heterologous proteins in yeast employing truncated alpha-factor leader sequences |
EP0324274A1 (en) | 1987-12-30 | 1989-07-19 | Chiron Corporation | Improved expression and secretion of heterologous proteins in yeast employing truncated alpha-factor leader sequences |
US5602034A (en) | 1987-12-30 | 1997-02-11 | Chiron Corporation | Expression and secretion of heterologous proteins in yeast employing truncated alpha-factor leader sequences |
WO1989006699A1 (en) | 1988-01-13 | 1989-07-27 | Institut Pasteur | Dna probe specific for hemolytic listeria |
EP0340986A2 (en) | 1988-05-06 | 1989-11-08 | Chiron Corporation | High level expression of proteins in yeast |
US6183985B1 (en) | 1988-05-06 | 2001-02-06 | Chiron Corporation | High level expression of proteins in yeast |
US5674706A (en) | 1988-05-06 | 1997-10-07 | Chiron Corporation | High level expression of proteins in yeast |
US5583023A (en) | 1988-05-31 | 1996-12-10 | Institut National De La Recherche Agronomique | Modified baculovirus, its preparation process and its application as a gene expression vector |
WO1990001556A1 (en) | 1988-08-05 | 1990-02-22 | Mount Sinai School Of Medicine Of The City University Of New York | In vivo infection of live insects with a recombinant baculovirus |
WO1990002186A1 (en) | 1988-08-16 | 1990-03-08 | Polly Roy | Production of bluetongue virus non-structural proteins using a baculovirus expression vector |
WO1990002566A1 (en) | 1988-09-02 | 1990-03-22 | Molecular Engineering Associates, Inc. | Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof |
WO1990005785A1 (en) | 1988-11-18 | 1990-05-31 | The Regents Of The University Of California | Method for site-specifically incorporating unnatural amino acids into proteins |
WO1990010078A1 (en) | 1989-02-23 | 1990-09-07 | University Of Ottawa | Improved baculovirus expression system capable of producing foreign gene proteins at high levels |
EP0460071A1 (en) | 1989-02-24 | 1991-12-11 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
WO1990010277A1 (en) | 1989-02-24 | 1990-09-07 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1990014428A1 (en) | 1989-05-17 | 1990-11-29 | University Of Georgia Research Foundation, Inc. | Improved baculovirus expression vectors |
WO1991000357A1 (fr) | 1989-06-30 | 1991-01-10 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5571709A (en) | 1990-07-18 | 1996-11-05 | Institut National De La Recherche Agronomique | Modified baculovirus and baculovirus expression vectors |
WO1992001801A1 (fr) | 1990-07-18 | 1992-02-06 | Institut National De La Recherche Agronomique (Inra) | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus |
US5629203A (en) | 1990-07-20 | 1997-05-13 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
WO1992003628A1 (fr) | 1990-08-14 | 1992-03-05 | Jean Arbona | Unite de soins modulaire |
US5324639A (en) | 1990-09-04 | 1994-06-28 | The Salk Institute Biotechnology/Industrial Assoc, Inc. | Production of insulin-like growth factor-1 in methylotrophic yeast cells |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5231178A (en) | 1991-01-16 | 1993-07-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Method for the purification of intact, correctly-folded insulin-like growth factor-1 |
WO1992016619A1 (en) | 1991-03-19 | 1992-10-01 | Us Army | Expression of influenza nucleoprotein antigens in baculovirus |
US6013433A (en) | 1991-04-26 | 2000-01-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus |
US6126944A (en) | 1991-04-26 | 2000-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5290686A (en) | 1991-07-31 | 1994-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Expression of influenza a M2 protein in baculovirus |
WO1993003173A1 (en) | 1991-07-31 | 1993-02-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Improved expression of influenza a m2 protein in baculovirus and uses of m2 protein |
WO1993015189A1 (en) | 1992-01-29 | 1993-08-05 | Consiglio Nazionale Delle Ricerche | A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes |
WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
WO1994009027A1 (en) | 1992-10-13 | 1994-04-28 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
WO1994017039A1 (en) | 1993-01-19 | 1994-08-04 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
WO1994018247A1 (en) | 1993-02-02 | 1994-08-18 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
US5858368A (en) | 1993-09-13 | 1999-01-12 | Protein Sciences Corporation | Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605827A (en) | 1993-11-04 | 1997-02-25 | The Ohio State University Research Foundation | Infectious bursal disease virus VP2 fusion protein expressed by baculovirus |
US5900461A (en) | 1993-11-12 | 1999-05-04 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
WO1995020672A1 (fr) | 1994-01-31 | 1995-08-03 | Proteine Performance | Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux |
US5753220A (en) | 1994-03-15 | 1998-05-19 | Katakura Industries Co., Ltd. | Cysteine protease gene defective baculovirus, process for its production, and process for the production of economic protein by using the same |
WO1996006161A1 (en) | 1994-08-24 | 1996-02-29 | Boyce Thompson Institute For Plant Research, Inc. | Establishment of trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6235710B1 (en) | 1994-12-16 | 2001-05-22 | Ortho Pharmaceutical Corporation | Spray dried erythropoietin |
US6001800A (en) | 1994-12-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | Spray dried erythropoietin |
WO1996021469A1 (en) | 1995-01-10 | 1996-07-18 | Shearwater Polymers, Inc. | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6183987B1 (en) | 1995-02-17 | 2001-02-06 | Stichting Institut Voor Dierhouderij En Diergezonheld | Production of biologically active recombinant bovine follicle stimulation hormone (rec bFSH) in the baculovirus expression system |
WO1996025496A1 (en) | 1995-02-17 | 1996-08-22 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM |
WO1996029400A1 (fr) | 1995-03-23 | 1996-09-26 | Institut National De La Recherche Agronomique (Inra) | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en ×uvre dudit procede |
US5939285A (en) | 1995-03-23 | 1999-08-17 | Institut National De La Recherche Scientifique Agronomique (Inra) | Method for regulating the expression of a gene in a baculovirus using a retinoic acid receptor binding site and vector therefor |
US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
US6096304A (en) | 1995-05-17 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Recombinant baculovirus insecticides |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5861279A (en) | 1996-01-17 | 1999-01-19 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
WO1997026332A1 (en) | 1996-01-17 | 1997-07-24 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
WO1998026080A1 (en) | 1996-12-13 | 1998-06-18 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US6083723A (en) | 1996-12-13 | 2000-07-04 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US6312923B1 (en) | 1996-12-13 | 2001-11-06 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
EP0946736A1 (en) | 1996-12-13 | 1999-10-06 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US6017731A (en) | 1996-12-13 | 2000-01-25 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US20020055169A1 (en) | 1996-12-13 | 2002-05-09 | Chiron Corporation | Method for expression of heterologous proteins in yeast |
US6361969B1 (en) | 1997-02-19 | 2002-03-26 | Chiron S.P.A. | Expression of heterologous proteins |
WO1998037208A1 (en) | 1997-02-19 | 1998-08-27 | Chiron S.P.A. | Expression of heterologous proteins |
US5965393A (en) | 1997-07-01 | 1999-10-12 | National Institute Of Immunology | Method for enhancing foreign gene expression in baculovirus expression vector system |
US6608183B1 (en) | 1997-07-14 | 2003-08-19 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
WO1999005297A1 (en) | 1997-07-25 | 1999-02-04 | Zeneca Limited | T7 promoter-based expression system |
WO1999007862A1 (en) | 1997-08-05 | 1999-02-18 | Chiron Corporation | Novel pichia pastoris gene sequences and methods for their use |
WO1999009193A1 (de) | 1997-08-15 | 1999-02-25 | Hepavec Ag Für Gentherapie | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
WO1999010515A1 (en) | 1997-08-21 | 1999-03-04 | University Technologies International, Inc. | Baculovirus artificial chromosomes and methods of use |
US6521427B1 (en) | 1997-09-16 | 2003-02-18 | Egea Biosciences, Inc. | Method for the complete chemical synthesis and assembly of genes and genomes |
WO1999031257A2 (en) | 1997-12-18 | 1999-06-24 | Stichting Instituut Voor Dierhouderij En Diergezondheid | Protein expression in baculovirus vector expression systems |
US6225060B1 (en) | 1998-03-04 | 2001-05-01 | Onyx Pharmaceuticals, Inc. | Baculovirus expression system and method for high throughput expression of genetic material |
WO1999045130A1 (en) | 1998-03-04 | 1999-09-10 | Onyx Pharmaceuticals, Inc. | Baculovirus expression system and method for high throughput expression of genetic material |
WO1999051721A1 (en) | 1998-04-03 | 1999-10-14 | Seok Kwon Kang | Novel recombinant baculovirus, construction method thereof and insect pesticidal composition containing the same |
US6338846B1 (en) | 1998-04-03 | 2002-01-15 | Seok-Kwon Kang | Recombinant baculovirus, construction method thereof and insect pesticidal composition containing the same |
US6168932B1 (en) | 1998-07-13 | 2001-01-02 | Parker Hughes Institute | Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system |
US6245528B1 (en) | 1998-07-28 | 2001-06-12 | Academia Sinica | Latent baculovirus expression system |
US6368825B1 (en) | 1998-08-10 | 2002-04-09 | Academia Sinica | Baculovirus containing minimal CMV promoter |
WO2000020032A1 (en) | 1998-10-06 | 2000-04-13 | Trustees Of Dartmouth College | RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY |
WO2000055345A2 (en) | 1999-03-17 | 2000-09-21 | Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
US6342216B1 (en) | 1999-03-17 | 2002-01-29 | The Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
WO2000055353A1 (en) | 1999-03-17 | 2000-09-21 | The Board Of Trustees Of The Leland Stanford Junior University | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system |
US20020081660A1 (en) | 1999-03-17 | 2002-06-27 | Swartz James R. | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel ATP regeneration system |
US6337191B1 (en) | 1999-03-22 | 2002-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Vitro protein synthesis using glycolytic intermediates as an energy source |
WO2001005956A2 (en) | 1999-07-15 | 2001-01-25 | Boyce Thompson Institute For Plant Research, Inc. | Sialyation of n-linked glycoproteins in the baculovirus expression vector system |
US6261805B1 (en) | 1999-07-15 | 2001-07-17 | Boyce Thompson Institute For Plant Research, Inc. | Sialyiation of N-linked glycoproteins in the baculovirus expression vector system |
WO2001027301A2 (en) | 1999-10-15 | 2001-04-19 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
US20020042097A1 (en) | 2000-05-26 | 2002-04-11 | Tirrell David A. | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
WO2001090390A1 (en) | 2000-05-26 | 2001-11-29 | Ark Therapeutics Limited | Use of baculovirus vectors in gene therapy |
WO2002006305A1 (fr) | 2000-07-17 | 2002-01-24 | Institute Of Immunology Co., Ltd. | Procede permettant de recueillir l'enveloppe virale d'un baculovirus |
US20030208046A1 (en) | 2000-09-08 | 2003-11-06 | Hunter Christie L. | Pseudo native chemical ligation |
US20030082575A1 (en) | 2001-04-19 | 2003-05-01 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
US20030108885A1 (en) | 2001-04-19 | 2003-06-12 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs |
WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
WO2002098902A2 (en) | 2001-06-05 | 2002-12-12 | Geneprot, Inc. | Improved native chemical ligation with three or more components |
US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
US20030143596A1 (en) | 2001-11-07 | 2003-07-31 | Shearwater Corporation | Branched polymers and their conjugates |
WO2003042235A2 (en) | 2001-11-14 | 2003-05-22 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
WO2004035743A2 (en) | 2002-10-16 | 2004-04-29 | The Scripps Research Institute | Site specific incorporation of keto amino acids into proteins |
US20040198637A1 (en) | 2002-12-22 | 2004-10-07 | The Scripps Research Institute | Protein arrays |
WO2004094593A2 (en) | 2003-04-17 | 2004-11-04 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
Non-Patent Citations (352)
Title |
---|
"GEL FILTRATION: PRINCIPLES AND METHODS", AMERSHAM BIOSCIENCES |
"HYDROPHOBIC INTERACTION CHROMATOGRAPHY HANDBOOK: PRINCIPLES AND METHODS", AMERSHAM BIOSCIENCES |
"Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.", 1999, LIPPINCOTT WILLIAMS & WILKINS |
"Remington: The Science and Practice of Pharmacy, 19th ed.", 1995, MACK PUBLISHING COMPANY |
"The Pharmacological Basis of Therapeutics, 9th ed.", 1996, MCGRAW-HILL |
A. FORSTER ET AL., PROC. NATL ACAD. SCI. (USA), vol. 100, no. 11, 2003, pages 6353 - 6357 |
A. FRANKEL ET AL., CHEMISTRY & BIOLOGY, vol. 10, 2003, pages 1043 - 1050 |
ABUCHOWSKI ET AL., CANCER BIOCHEM. BIOPHYS., vol. 7, 1984, pages 175 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
AMANN ET AL., GENE, vol. 25, 1983, pages 167 |
ANDERSON ET AL.: "Exploring the Limits of Codon and Anticodon Size", CHEMISTRY AND BIOLOGY, vol. 9, 2002, pages 237 - 244 |
ANDRESZ ET AL., MAKROMOL. CHEM., vol. 179, 1978, pages 301 |
ARAKAWA ET AL., PHARM. RES., vol. 8, no. 3, 1991, pages 285 - 291 |
ARNOLD: "Protein engineering for unusual environments", CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, 1993, pages 450 - 455 |
ATLAS AND PARKS: "The Handbook of Microbiological Media", 1993, CRC PRESS |
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1994, pages 16.9 - 16.11 |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994 |
BAIN, J.D.; GLABE, C.G.; DIX, T.A.; CHAMBERLIN, A.R.; DIALA, E.S.: "Biosynthetic site-specific Incorporation of a non-natural amino acid into a polypeptide", J. AM CHEM SOC, vol. 111, 1989, pages 8013 - 8014 |
BALLANCE ET AL., B . B . RES. C ., vol. 112, 1983, pages 284 - 89 |
BARANY ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 189 - 193 |
BASS ET AL.: "Mutant Trp repressors with new DNA-binding specificities", SCIENCE, vol. 242, 1988, pages 240 - 245 |
BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081 |
BAZAN, F., IMMUNOLOGY TODAY, vol. 11, 1990, pages 350 - 354 |
BAZAN, J. F., SCIENCE, vol. 257, 1992, pages 410 - 411 |
BAZAN, J. F.; MCKAY, D. B., SCIENCE, vol. 257, 1992, pages 410 - 413 |
BEACH; NURSE, NATURE, vol. 300, 1981, pages 706 |
BEAUCHAMP ET AL., ANAL. BIOCHEM., vol. 131, 1983, pages 25 |
BERGER; KIMMEL: "Methods in Enzymology", vol. 152, ACADEMIC PRESS, INC., article "Guide to Molecular Cloning Techniques" |
BOLLAG ET AL.: "Protein Methods, 2nd ed.", 1996, WILEY-LISS |
BOTSTEIN; SHORTLE: "Strategies and applications of in vitro mutagenesis", SCIENCE, vol. 229, 1985, pages 1193 - 1201 |
BROADHEAD, J. ET AL.: "The Spray Drying of Pharmaceuticals", DRUG DEV. IND. PHARM, vol. 18, no. 11, 12, 1992, pages 1169 - 1206 |
BRUNNER, J.: "New Photolabeling and crosslinking methods", ANNU. REV BIOCHEM, 1993, pages 483 - 514 |
BUCHNER ET AL., ANAL. BIOCHEM., vol. 205, 1992, pages 263 - 270 |
BUCKMANN ET AL., MAKROMOL. CHEM., vol. 182, 1981, pages 1379 |
C. MINKS; R. HUBER; L. MORODER; N. BUDISA, ANAL. BIOCHEM., vol. 284, 2000, pages 29 - 34 |
C.J. NOREN; S.J. ANTHONY-CAHILL; M.C. GRIFFITH; P.G. SCHULTZ: "A general method for site-specific incorporation of unnatural amino acids into proteins", SCIENCE, vol. 244, 1989, pages 182 - 188 |
CAI ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 10, 1997, pages 263 |
CARBONELL ET AL., J. V ., vol. 56, 1985, pages 153 |
CAREY; SUNDBERG: "ADVANCED ORGANIC CHEMISTRY, 4th ed.", vol. A, B, 2000, PLENUM |
CARTER ET AL.: "Improved oligonucleotide site-directed mutagenesis using M13 vectors", NUCL. ACIDS RES., vol. 13, 1985, pages 4431 - 4443 |
CARTER: "Improved oligonucleotide-directed mutagenesis using M13 vectors", METHODS IN ENZYMOL., vol. 154, 1987, pages 382 - 403 |
CARTER: "Site-directed mutagenesis", BIOCHEM. J., vol. 237, 1986, pages 1 - 7 |
CHAIKEN, I.M.: "Semisynthetic peptides and proteins", CRC CRIT REV BIOCHEM, 1981, pages 255 - 301 |
CHANG ET AL., NATURE, vol. 198, 1977, pages 1056 |
CHIN ET AL., AM. CHEM. SOC., vol. 124, 2002, pages 9026 - 9027 |
CHIN ET AL., PROC. NATL. ACAD. SCI., vol. 99, 2002, pages 11020 - 11024 |
CHIN ET AL., SCIENCE, vol. 300, 2003, pages 964 - 967 |
CHIN, J. W. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 9026 - 9027 |
CHIN, J. W. ET AL., SCIENCE, vol. 301, 2003, pages 964 - 967 |
COREY, D.R.; SCHULTZ, P.G.: "Generation of a hybrid sequencespecific single-stranded deoxyribonuclease", SCIENCE, vol. 238, 1987, pages 1401 - 1403 |
CORNISH ET AL., AM. CHEM. SOC., vol. 118, 1996, pages 8150 - 8151 |
CREGG ET AL., M . CELL. B ., vol. 5, 1985, pages 3376 |
CRICK, F.J.C.; BARRETT, L; BRENNER, S; WATTS-TOBIN, R.: "General nature of the genetic code for proteins", NATURE, vol. 192, no. 4809, 1961, pages 1227 - 1232 |
D. A. DOUGHERTY, CURR. OPIN. CHEM. BIOL., vol. 4, 2000, pages 645 |
DALE ET AL.: "Oligonucleotide-directed random mutagenesis using the phosphorothioate method", METHODS MOL. BIOL., vol. 57, 1996, pages 369 - 374 |
DAS ET AL., J. B ., vol. 158, 1984, pages 1165 |
DAVIDOW ET AL., C . GENET., vol. 10, 1985, pages 380 |
DAVIS ET AL., SCIENCE, vol. 260, 1993, pages 1805 - 1808 |
DE BOER ET AL., P . N . A . S ., vol. 80, 1983, pages 21 |
DE LOUVENCOURT ET AL., J. B ., vol. 154, 1983, pages 737 |
DEBINSKI ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 14065 - 14070 |
DELGADO ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 9, 1992, pages 249 - 304 |
DENNIS ET AL., J. BIOL. CHEM., vol. 277, no. 38, 2002, pages 35035 - 35043 |
DEUTSCHER: "Methods in Enzymology Vol. 182: Guide to Protein Purification", vol. 182, 1990, ACADEMIC PRESS, INC. |
DIEDERICHS, K. ET AL., SCIENCE, vol. 154, 1991, pages 1779 - 1782 |
DOLPHIN ET AL., NATURE GENETICS, vol. 17, 1997, pages 491 |
DOUGHERTY: "Current Opinion in Chemical Biology", vol. 4, 2000, article "Unnatural Amino Acids as Probes of Protein Structure and Function", pages: 645 - 652 |
DOUGHERTY: "Unnatural Amino Acids as Probes of Protein Structure and Function", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 4, 2000, pages 645 - 652 |
ECKSTEIN, F. AND LILLEY, D.M.J.: "Nucleic Acids & Molecular Biology", 1987, SPRINGER VERLAG, article KUNKEL: "The efficiency of oligonucleotide directed mutagenesis" |
EGHTEDARZADEH; HENIKOFF: "Use of oligonucleotides to generate large deletions", NUCL. ACIDS RES., vol. 14, 1986, pages 5115 |
ELLING ET AL., BIOTECH. APPL. BIOCHEM., vol. 13, 1991, pages 354 |
ELLIOTT ET AL., J. PROTEIN C ., vol. 9, 1990, pages 95 |
ELLMAN, J.A.; MENDEL, D.; ANTHONY-CAHILL, S.; NOREN, C.J.; SCHULTZ, P.G.: "Biosynthetic method for introducing unnatural amino acids site-specifically into proteins", METHODS IN ENZ., vol. 202, 1992, pages 301 - 336 |
ELLMAN, J.A.; MENDEL, D.; SCHULTZ, P.G.: "Site-specific incorporation of novel backbone structures into proteins", SCIENCE, vol. 255, 1992, pages 197 - 200 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3688 - 3692 |
F. HAMANO-TAKAKU; T. IWAMA; S. SAITO-YANO; K. TAKAKU; Y. MONDEN; M. KITABATAKE; D. SOIL; S. NISHIMURA, J. BIOL. CHEM., vol. 275, no. 51, 2000, pages 40324 - 40328 |
F.M. AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1999, A JOINT VENTURE BETWEEN GREENE PUBLISHING ASSOCIATES, INC. AND JOHN WILEY & SONS, INC. |
F: "The Regulation of Baculovirus Gene Expression", THE MOLECULAR BIOLOGY OF BACULOVIRUSES, 1986 |
FIESCHKO ET AL., B . B ., vol. 29, 1987, pages 1113 |
FRASER ET AL., IN VITRO CELL. D . B ., vol. 25, 1989, pages 225 |
FRESHNEY: "Culture of Animal Cells, a Manual of Basic Technique, 3rd ed.", 1994, WILEY-LISS |
FRITZ ET AL.: "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro", NUCL. ACIDS RES., vol. 16, 1988, pages 6987 - 6999 |
FROMM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 5824 |
G. TURCATTI; K. NEMETH; M. D. EDGERTON; U. MESETH; F. TALABOT; M. PEITSCH; J. KNOWLES; H. VOGEL; A. CHOLLET, J. BIOL. CHEM., vol. 271, no. 33, 1996, pages 19991 - 19998 |
GAILLARDIN ET AL., C . GENET, vol. 10, 1985, pages 49 |
GAMBORG AND PHILLIPS: "Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual", 1995, SPRINGER-VERLAG |
GELLISSEN ET AL., A VAN L, vol. 62, no. 1-2, 1992, pages 79 - 93 |
GHERNA ET AL.: "The ATCC Catalogue of bacteria and bacteriophage", 1992, ATCC |
GILLAM; SMITH, GENE, vol. 8, 1979, pages 81 |
GLEESON ET AL., J. GEN. M ., vol. 132, 1986, pages 3459 |
GOEDDEL ET AL., NUC. ACIDS RES., vol. 8, 1980, pages 4057 |
GOEDDEL, METHODS IN ENZYMOLOGY, vol. 185, 1990, pages 3 - 7 |
GOODSON ET AL., BIO/TECHNOLOGY, vol. 8, 1990, pages 343 |
GRAVES ET AL., BIOCHEMISTRY, vol. 37, 1998, pages 6050 |
GREENE; WUTS: "Protective Groups in Organic Synthesis, 3rd ed.", 1999, JOHN WILEY & SONS |
GRUNDSTROM ET AL.: "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis", NUCL. ACIDS RES., vol. 13, 1985, pages 3305 - 3316 |
GUCKIAN; KOOL, ANGEW. CHEM. INT. ED. ENGL., vol. 36, no. 24, 1998, pages 2825 - 2828 |
H. DUEWEL; E. DAUB; V. ROBINSON; J. F. HONEK, BIOCHEMISTRY, vol. 36, 1997, pages 3404 - 3416 |
H. HANG; C. BERTOZZI, ACC. CHEM. RES., vol. 34, no. 9, 2001, pages 727 - 736 |
H. LIU ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 1702 - 1703 |
HARRIS & ANGAL: "PROTEIN PURIFICATION METHODS, A PRACTICAL APPROACH", 1989, IRL PRESS, article PRENETA AZ, pages: 293 - 306 |
HARRIS & ZALIPSKY: "Poly(ethylene glycol) Chemistry & Biological Applications", 1997, ACS, article OLSON ET AL., pages: 170 - 181 |
HARRIS ET AL., J. POLYM. SCI. CHEM. ED., vol. 22, 1984, pages 341 |
HARRIS, MACROMOL. CHEM. PHYS., vol. C25, 1985, pages 325 - 373 |
HARRIS; ANGAL: "Protein Purification Applications: A Practical Approach", 1990, IRL PRESS AT OXFORD |
HARRIS; ANGAL: "Protein Purification Methods: A Practical Approach", IRL PRESS AT OXFORD |
HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 |
HESS ET AL., J. ADV. ENZYME R ., vol. 7, 1969, pages 149 - 167 |
HILL ET AL., PROC. NATL. ACAD. SCI.USA, vol. 90, 1993, pages 5167 |
HINNEN ET AL., P . N . A . S . USA, vol. 75, 1978, pages 1929 |
HIRAO ET AL.: "An unnatural base pair for incorporating amino acid analogues into protein", NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 177 - 182 |
HITZEMAN ET AL., J. B . C ., vol. 255, no. 4, 1980, pages 12073 - 12080 |
HOFMANN, K.; BOHN, H.: "Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment", J. AM CHEM, vol. 88, no. 24, 1966, pages 5914 - 5919 |
HOHSAKA ET AL., J. AM. CHEM. SOC., vol. 121, 1999, pages 12194 - 12195 |
HOHSAKA ET AL., J. AM. CHEM. SOC., vol. 121, 1999, pages 34 - 40 |
HOLLAND ET AL., BIOCHEMISTRY, vol. 17, no. 23, 1978, pages 4900 - 4907 |
HOLLAND ET AL., J. B . C ., vol. 256, 1981, pages 1385 |
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO. |
HSIAO ET AL., P . N . A . S . USA, vol. 76, 1979, pages 3829 |
HUDSON, CURR. OPIN. BIOTECHNOL., vol. 9, 1998, pages 395 - 402 |
HWANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4030 - 4034 |
I. A. LORIMER; I. PASTAN, NUCLEIC ACIDS RES., vol. 23, 1995, pages 3067 - 8 |
I. GRESSER: "Interferon", vol. 3, 1981, article WEISSMANN: "The cloning of interferon and other mistakes" |
ITO ET AL., J. B ., vol. 153, 1983, pages 163 |
J. C. M. VAN HEST; K. L. KIICK; D. A. TIRRELL, J. AM. CHEM. SOC., vol. 122, 2000, pages 1282 - 1288 |
J. C. M. VANHEST; D. A. TIRRELL, FEBS LETT., vol. 428, 1998, pages 68 - 70 |
J. C. MILLER; S. K. SILVERMAN; P. M. ENGLAND; D. A. DOUGHERTY; H. A. LESTER, NEURON, vol. 20, 1998, pages 619 - 624 |
J. CHIN ET AL., SCIENCE, vol. 301, 2003, pages 964 - 7 |
J. O. BOLES; K. LEWINSKI; M. KUNKLE; J. D. ODOM; B. DUNLAP; L. LEBIODA; M. HATADA, NAT. STRUCT. BIOL., vol. 1, 1994, pages 283 - 284 |
J. P. GALLIVAN; H. A. LESTER; D. A. DOUGHERTY, CHEM. BIOL., vol. 4, no. 10, 1997, pages 739 - 749 |
J. W. CHIN ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 2002, pages 9026 - 9027 |
J. W. CHIN ET AL., PNAS UNITED STATES OF AMERICA, vol. 99, no. 17, 2002, pages 11020 - 11024 |
J. W. CHIN; P. G. SCHULTZ, CHEMBIOCHEM, vol. 3, no. 11, 2002, pages 1135 - 1137 |
J.D. BAIN; C.G. GLABE; T.A. DIX; A.R. CHAMBERLIN; E.S. DIALA: "Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide", J. AM. CHEM. SOC., vol. 111, 1989, pages 8013 - 8014 |
JACKSON, D.Y.; BURNIER, J.; QUAN, C.; STANLEY, M.; TOM, J.; WELLS, J.A.: "A Designed Peptide Ligase for Total Synthesis of Ribonuclease A with Unnatural Catalytic Residues", SCIENCE, vol. 266, 1994, pages 243 - 247 |
JAKOBSSON ET AL., J. B . C ., vol. 271, 1996, pages 22203 |
JANSON; RYDEN: "Protein Purification: Principles, High Resolution Methods and Applications, 2nd ed.", 1998, WILEY-VCH |
JOPPICH ET AL., MAKROMOL. CHEM., vol. 180, 1979, pages 1381 |
K. L. KIICK; D. A. TIRRELL, TETRAHEDRON, vol. 56, 2000, pages 9487 - 9493 |
KAISER, E.T.: "Synthetic approaches to biologically active peptides and proteins including enyzmes", ACC CHEM RES, vol. 22, no. 2, 1989, pages 47 - 54 |
KAISER, E.T.; LAWRENCE D.S.; ROKITA, S.E.: "The chemical modification of enzymatic specificity", ANN. REV BIOCHEM, vol. 54, 1985, pages 565 - 595 |
KAISER, E.T.; LAWRENCE, D.S.: "Chemical mutation of enyzme active sites", SCIENCE, vol. 226, 1984, pages 505 - 511 |
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787 |
KELLY; HYNES, EMBO J., vol. 4, 1985, pages 475 - 479 |
KIICK ET AL.: "Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligtation", PNAS, vol. 99, no. 1, 2002, pages 19 - 24 |
KIM, D.-M.; J.R. SWARTZ, BIOTECHNOLOGY AND BIOENGINEERING, vol. 66, no. 3, 1999, pages 180 - 188 |
KIM, D.-M.; J.R. SWARTZ, BIOTECHNOLOGY AND BIOENGINEERING, vol. 74, no. 4, 2001, pages 309 - 316 |
KIM, D.-M.; J.R. SWARTZ, BIOTECHNOLOGY LETTERS, vol. 22, 2000, pages 1537 - 1542 |
KIM, D.-M.; J.R. SWARTZ, BIOTECHNOLOGY PROGRESS, vol. 16, 2000, pages 385 - 390 |
KING; POSSEE: "THE BACULOVIRUS SYSTEM: A LABORATORY GUIDE", 1992 |
KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141 |
KITTS, NAR, vol. 18, no. 19, 1990, pages 5667 |
KLAUS ET AL., J. MOL. BIOL., vol. 274, 1997, pages 661 |
KLEIN ET AL., NATURE, vol. 327, 1987, pages 70 - 73 |
KOBAYASHI ET AL., NATURE STRUCTURAL BIOLOGY, vol. 10, no. 6, 2003, pages 425 - 432 |
KOGAN, SYNTHETIC COMM., vol. 22, 1992, pages 2417 |
KOOL, CURR. OPIN. CHEM. BIOL., vol. 4, 2000, pages 602 - 608 |
KOST ET AL., GENE, vol. 190, 1997, pages 139 |
KRAMER ET AL.: "Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations", NUCL. ACIDS RES., vol. 16, 1988, pages 7207 |
KRAMER ET AL.: "Point Mismatch Repair", CELL, vol. 38, 1984, pages 879 - 887 |
KRAMER ET AL.: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCL. ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KRAMER; FRITZ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA", METHODS IN ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KREITMAN; PASTAN, BIOCONJUG. CHEM., vol. 4, 1993, pages 581 - 585 |
KRIEG, U.C.; WALTER, P.; HOHNSON, A.E.: "Photocrosslinking of the signal sequence of nascent preprolactin of the 54-kilodalton polypeptide of the signal recognition particle", PROC. NATL. ACAD. SCI, vol. 83, 1986, pages 8604 - 8608 |
KRIEGLER: "Gene Transfer and Expression: A Laboratory Manual", 1990 |
KUNITANI ET AL., J. C ., vol. 359, 1986, pages 391 - 402 |
KUNKEL ET AL.: "Rapid and efficient site-specific mutagenesis without phenotypic selection", METHODS IN ENZYMOL., vol. 154, 1987, pages 367 - 382 |
KUNKEL: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492 |
KUNZE ET AL., J. BASIC M ., vol. 25, 1985, pages 141 |
KURTZ ET AL., M . CELL. B ., vol. 6, 1986, pages 142 |
KURTZHALS ET AL., BIOCHEM. J., vol. 312, 1995, pages 725 - 731 |
L. WANG ET AL., SCIENCE, vol. 292, 2001, pages 498 - 500 |
L. WANG; P. G. SCHULTZ, CHEM. COMM., 2002, pages 1 - 11 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277 |
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105 |
LASIC D AND PAPAHADJOPOULOS D: "MEDICAL APPLICATIONS OF LIPOSOMES", 1998 |
LEE ET AL., J. INTERFERON CYTOKINE RES., vol. 15, 1995, pages 341 |
LIBERMAN, H.A. AND LACHMAN, L.: "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER |
LIEBMAN ET AL., BIOTECHNIQUES, vol. 26, no. 1, 1999, pages 36 |
LING ET AL.: "Approaches to DNA mutagenesis: an overview", ANAL BIOCHEM., vol. 254, no. 2, 1997, pages 157 - 178 |
LIU, D.R.; SCHULTZ, P.G.: "Progress toward the evolution of an organism with an expanded genetic code", PNAS UNITED STATES, vol. 96, 1999, pages 4780 - 4785 |
LUCKOW; SUMMERS, VIROLOGY, vol. 170, 1989, pages 31 - 39 |
M. IBBA; H. HENNECKE, FEBS LETT., vol. 364, 1995, pages 272 - 275 |
M. IBBA; P. KAST; H. HENNECKE, BIOCHEMISTRY, vol. 33, 1994, pages 7107 - 7112 |
M. W. NOWAK; P. C. KEARNEY; J. R. SAMPSON; M. E. SAKS; C. G. LABARCA; S. K. SILVERMAN; W. G. ZHONG; J. THORSON; J. N. ABELSON; N., SCIENCE, vol. 268, 1995, pages 439 - 442 |
M.W. NOWAK ET AL., SCIENCE, vol. 268, 1995, pages 439 - 42 |
MA ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 7939 - 7945 |
MAGLIERY: "Expanding the Genetic Code: Selection of Efficient Suppressors of Four-base Codons and Identification of ''Shifty'' Four-base Codons with a Library Approach in Escherichia coli", J. MOL. BIOL., vol. 307, 2001, pages 755 - 769 |
MAHAL ET AL., SCIENCE, vol. 276, 1997, pages 1125 - 1128 |
MAKRIDES ET AL., J. PHARMACOL. EXP. THER., vol. 277, no. 1, 1996, pages 534 - 542 |
MAMOT C ET AL., CANCER RES., vol. 63, 2003, pages 3154 - 3161 |
MANDECKI: "Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 7177 - 7181 |
MANN; KING, J. GEN. V ., vol. 70, 1989, pages 3501 |
MARCH: "ADVANCED ORGANIC CHEMISTRY, 5th ed.", 2001, WILEY |
MATTHEWS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 9471 - 9476 |
MAYNARD; GEORGIOU, ANNU. REV. BIOMED. ENG., vol. 2, 2000, pages 339 - 76 |
MCMINN ET AL., J. AM. CHEM. SOC., vol. 121, 1999, pages 11585 - 11586 |
MEGGERS ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 10714 - 10715 |
MEHL ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 935 - 939 |
MENDEL, D.; CORNISH, V.W.; SCHULTZ, P.G.: "Site-Directed Mutagenesis with an Expanded Genetic Code", ANNU REV BIOPHYS. BIOMOL STRUCT., vol. 24, 1995, pages 435 - 62 |
METHODS IN ENZYMOL., vol. 100, 1983, pages 468 - 500 |
METHODS IN ENZYMOL., vol. 154, 1987, pages 329 - 350 |
METHODS IN ENZYMOLOGY, vol. 154 |
MILBURN ET AL., NATURE, vol. 363, 1993, pages 172 - 176 |
MILLER ET AL., ANN. REV. M ., vol. 42, 1988, pages 177 |
MILLER ET AL., B, vol. 4, 1989, pages 91 |
MIYANOHARA ET AL., P . N . A . S . USA, vol. 80, 1983, pages 1 |
MOORE ET AL., J. MOL. BIOL., vol. 298, 2000, pages 195 - 205 |
MOSBACH ET AL., NATURE, vol. 302, 1983, pages 543 - 545 |
MOTT, H. R.; CAMPBELL, I. D., CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 5, 1995, pages 114 - 121 |
MOTT; CAMPBELL, CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 5, 1995, pages 114 - 121 |
MURGOLO ET AL., PROTEINS, vol. 17, 1993, pages 62 |
N. BUDISA ET AL., FASEB J., vol. 13, 1999, pages 41 - 51 |
N. BUDISA; B. STEIPE; P. DEMANGE; C. ECKERSKORN; J. KELLERMANN; R. HUBER, EUR. J. BIOCHEM., vol. 230, 1995, pages 788 - 796 |
N. BUDISA; C. MINKS; S. ALEFELDER; W. WENGER; F. M. DONG; L. MORODER; R. HUBER, FASEB J., vol. 13, 1999, pages 41 - 51 |
N. BUDISA; W. KARNBROCK; S. STEINBACHER; A. HUMM; L. PRADE; T. NEUEFEIND; L. MORODER; R. HUBER, J. MOL. BIOL., vol. 270, 1997, pages 616 - 623 |
N. SHARMA; R. FURTER; P. KAST; D. A. TIRRELL, FEBS LETT., vol. 467, 2000, pages 37 - 40 |
NAKAMAYE; ECKSTEIN: "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis", NUCL. ACIDS RES., vol. 14, 1986, pages 9679 - 9698 |
NAKATSUKA, T.; SASAKI, T.; KAISER, E.T.: "Peptide segment coupling catalyzed by the semisynthetic enzyme thiosubtilisin", J AM CHEM SOC, vol. 109, 1987, pages 3808 - 3810 |
NAMBIAR ET AL.: "Total synthesis and cloning of a gene coding for the ribonuclease S protein", SCIENCE, vol. 223, 1984, pages 1299 - 1301 |
NEET, K.E.; NANCI A; KOSHLAND, D.E.: "Properties of thiol-subtilisin", J BIOL. CHEM, vol. 243, no. 24, 1968, pages 6392 - 6401 |
NIELSEN UB ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1591, no. 1-3, 2002, pages 109 - 118 |
NOMURA ET AL., J. B . C ., vol. 273, no. 22, 1998, pages 13570 |
NOREN, C.J.; ANTHONY-CAHILL; GRIFFITH, M.C.; SCHULTZ, P.G.: "A general method for site-specific incorporation of unnatural amino acids into proteins", SCIENCE, vol. 244, 1989, pages 182 - 188 |
OFFORD, R.E.: "Protein engineering by chemical means?", PROTEIN ENG., vol. 1, no. 3, 1987, pages 151 - 157 |
OGAWA ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 3274 - 3278 |
OGAWA ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 8803 - 8804 |
OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608 |
O'REILLY ET AL: "BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL", 1992 |
P. E. DAWSON; S. B. H. KENT, ANNU. REV. BIOCHEM., vol. 69, 2000, pages 923 |
P. M. ENGLAND; Y. ZHANG; D. A. DOUGHERTY; H. A. LESTER, CELL, vol. 96, 1999, pages 89 - 98 |
PALVA ET AL., GENE, vol. 22, 1983, pages 229 - 235 |
PAONESSA ET AL., EMBO J., vol. 14, 1995, pages 1942 - 1951 |
PARK JW ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 1172 - 1181 |
PARK JW ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 1327 - 1331 |
PATNAIK, R.; J.R. SWARTZ, BIOTECHNIQUES, vol. 24, no. 5, 1998, pages 862 - 868 |
PAYNE ET AL.: "Plant Cell and Tissue Culture in Liquid Systems", 1992, JOHN WILEY & SONS, INC. |
PEARSON ET AL., ANAL BIOCHEM., vol. 124, 1982, pages 217 - 230 |
PENG ET AL., BIOTECHNIQUES, vol. 14, no. 2, 1993, pages 274 |
PEPINSKY RB., J. PHARMACOL. & EXP. THER., vol. 297, no. 3, 2001, pages 1059 - 66 |
PICCIRILLI ET AL., NATURE, vol. 343, 1990, pages 33 - 37 |
PIKAL, M., BIOPHARM., vol. 3, no. 9, 1990, pages 26 - 30 |
PITHA ET AL., EUR. J BIOCHEM., vol. 94, 1979, pages 11 |
POLGAR, L.B.: "M.L. A new enzyme containing a synthetically formed active site. Thiol-subtilisin", J. AM CHEM SOC, vol. 88, no. 13, 1966, pages 3153 - 3154 |
POLLACK, S.J.; NAKAYAMA, G.; SCHULTZ, P.G.: "Introduction of nucleophiles and spectroscopic probes into antibody combining sites", SCIENCE, vol. 1, no. 242, 1988, pages 1038 - 1040 |
POWERS ET AL., SCIENCE, vol. 256, 1992, pages 1673 - 1677 |
R. F. GOLDBERGER: "Biological Regulation and Development: Gene Expression", 1979, article STEITZ ET AL.: "Genetic signals and nucleotide sequences in messenger RNA" |
R. FURTER, PROTEIN SCI., vol. 7, 1998, pages 419 - 426 |
R. ROBERTS; J. SZOSTAK, PROC. NATL ACAD. SCI. (USA), vol. 94, 1997, pages 12297 - 12302 |
R. SCOPES: "Protein Purification", 1982, SPRINGER-VERLAG |
RADHAKRISHNAN ET AL., STRUCTURE, vol. 4, 1996, pages 1453 |
RAIBAUD ET AL., A . REV. GENET., vol. 18, 1984, pages 173 |
REDFIELD ET AL., BIOCHEMISTRY, vol. 30, 1991, pages 11029 - 11035 |
REILLY: "BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL", 1992 |
REVERSEY ET AL., J. B . C ., vol. 271, no. 39, 1996, pages 23607 - 10 |
RICHARDSON: "METHODS IN MOLECULAR BIOLOGY: BACULOVIRUS EXPRESSION PROTOCOLS", vol. 39, 1995 |
RIVIER ET AL., J. C ., vol. 268, 1983, pages 112 - 119 |
ROBERTS ET AL., NATURE, vol. 328, 1987, pages 731 |
ROGGENKAMP ET AL., M . GEN. GENET., vol. 202, 1986, pages 302 |
ROMANI ET AL., CHEMISTRY OF PEPTIDES AND PROTEINS, vol. 2, 1984, pages 29 |
ROMANOS ET AL., YEAST, vol. 8, no. 6, 1992, pages 423 - 488 |
ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98 |
ROWLES ET AL., J. B . C ., vol. 271, no. 37, 1996, pages 22376 |
SAKMAR; KHORANA: "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin)", NUCL. ACIDS RES., vol. 14, 1988, pages 6361 - 6372 |
SAMBROOK ET AL.: "Molecular Cloning - A Laboratory Manual, 2nd ed.", vol. 1-3, 1989, COLD SPRING HARBOR LABORATORY |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual, 3rd ed.", 2001 |
SAMBROOK ET AL.: "MOLECULAR CLONING: A LAB. MANUAL", 2001 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, article "Expression of cloned genes in Escherichia coli" |
SANDANA: "Bioseparation of Proteins", 1997, ACADEMIC PRESS, INC. |
SANDLER; KARO: "Polymer Synthesis", vol. 3, ACADEMIC PRESS, pages: 138 - 161 |
SANTORO ET AL., NATURE BIOTECHNOLOGY, vol. 20, October 2002 (2002-10-01), pages 1044 - 1048 |
SARTORE ET AL., APPL. BIOCHEM. BIOTECH., vol. 27, 1991, pages 45 |
SAWHNEY ET AL., MACROMOLECULES, vol. 26, 1993, pages 581 |
SAYERS ET AL.: "5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis", NUCL. ACIDS RES., vol. 16, 1988, pages 791 - 802 |
SAYERS ET AL.: "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide", NUCL. ACIDS RES., vol. 16, 1988, pages 803 - 814 |
SAYERS, J.R. ET AL.: "5',3' Exonuclease in phosphorothioate-based oligonucleotide-directed mutagenesis", NUCLEIC ACIDS RES, vol. 16, no. 3, 1988, pages 791 - 802 |
SAYERS, J.R.; SCHMIDT, W.; ECKSTEIN, F.: "5', 3' Exonuclease in phosphorothioate-based oligonucleotide-directed mutagenesis", NUCLEIC ACIDS RES, vol. 16, no. 3, 1988, pages 791 - 802 |
SCHMIDT ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 12, 1998, pages 323 |
SCHNEIDER, E. ET AL., PROTEIN EXPR. PURIF., vol. 6, no. 1, 1995, pages 10 - 14 |
SCHNOLZER, M.; KENT, S B H.: "Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease", SCIENCE, vol. 256, 1992, pages 221 - 225 |
SCOPES: "Protein Purification: Principles and Practice, 3rd ed.", 1993, SPRINGER VERLAG |
SCOUTEN, METHODS IN ENZYMOLOGY, vol. 135, 1987, pages 30 - 65 |
See also references of EP1828224A4 |
SHAO, J.; TAM, J., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899 |
SHIMATAKE ET AL., NATURE, vol. 292, 1981, pages 128 |
SHINE ET AL., NATURE, vol. 254, 1975, pages 34 |
SIEBER ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 456 - 460 |
SIFFERT ET AL., NATURE GENETICS, vol. 18, 1998, pages 45 |
SIKORSKI ET AL., GENETICS, vol. 112, 1998, pages 19 |
SILVENNOINEN, O.; IHLE, J. N., SIGNALLING BY THE HEMATOPOIETIC CYTOKINE RECEPTORS, 1996 |
SISK ET AL., J. V ., vol. 68, no. 2, 1994, pages 766 |
SJOLANDER ET AL., J, IMMUNOL. METHODS, vol. 201, 1997, pages 115 - 123 |
SMITH ET AL., M . CELL. B ., vol. 3, 1983, pages 2156 |
SMITH: "In vitro mutagenesis", ANN. REV. GENET., vol. 19, 1985, pages 423 - 462 |
STANLEY ET AL., J. B . C ., vol. 270, 1995, pages 4121 |
STEMMER: "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution", PROC. NATL. ACAD. SCI. USA., vol. 91, 1994, pages 10747 - 10751 |
STEMMER: "Rapid evolution of a protein in vitro by DNA shuffling", NATURE, vol. 370, no. 4, 1994, pages 389 - 391 |
STUDIER ET AL., J. M . B ., vol. 189, 1986, pages 113 |
SUMMERS; SMITH, TEXAS AGRICULTURAL EXPERIMENT STATION BULLETIN NO. 1555, 1987 |
SUMMERS; SMITH, TEXAS AGRICULTURAL EXPERIMENT STATION BULLETIN, 1987 |
SWITZER ET AL., J. AM. CHEM. SOC., vol. 111, 1989, pages 8322 - 8322 |
S-Z HU ET AL., CANCER RESEARCH, vol. 56, 1996, pages 3055 - 3061 |
T. LU; A. Y. TING; J. MAINLAND; L. Y. JAN; P. G. SCHULTZ; J. YANG, NAT. NEUROSCI., vol. 4, no. 3, 2001, pages 239 - 246 |
TABOR ET AL., PROC NATL. ACAD. SCI., vol. 82, 1985, pages 1074 |
TAE ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 7439 - 7440 |
TAYLOR ET AL.: "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA", NUCL. ACIDS RES., vol. 13, 1985, pages 8765 - 8785 |
TAYLOR ET AL.: "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA", NUCL. ACIDS RES., vol. 13, 1985, pages 8749 - 8764 |
TEICHER B: "CANCER DRUG DISCOVERY AND DEVELOPMENT", 2002, article DRUMMOND DC ET AL.: "Liposomal drug delivery systems for cancer therapy" |
TIJSSEN: "Overview of principles of hybridization and the strategy of nucleic acid assays", LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGYHYBRIDIZATION WITH NUCLEIC PROBES, 1993 |
TILBURN ET AL., GENE, vol. 26, 1983, pages 205 - 221 |
TILKINS ET AL: "CELL BIOLOGY: A LABORATORY HANDBOOK", 1998, pages: 145 - 154 |
TONDELLI ET AL., J. CONTROLLED RELEASE, vol. 1, 1985, pages 251 |
TROTTER; WOOD, METHODS IN MOLECULAR BIOLOGY, 1995, pages 39 |
TSCHUMPER ET AL., GENE, vol. 10, 1980, pages 157 |
U. SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556 |
V. DORING; H. D. MOOTZ; L. A. NANGLE; T. L. HENDRICKSON; V. DE CRECY-LAGARD; P. SCHIMMEL; P. MARLIERE, SCIENCE, vol. 292, 2001, pages 501 - 504 |
V. W. CORNISH; D. MENDEL; P. G. SCHULTZ, ANGEW. CHEM. INT. ED. ENGL., vol. 34, 1995, pages 621 - 633 |
VAN DEN BERG ET AL., B T, vol. 8, 1990, pages 135 |
VAN SOLINGEN ET AL., J. B ., vol. 130, 1977, pages 946 |
VERONESE ET AL., APPL. BIOCHEM. BIOTECH., vol. 11, 1985, pages 141 |
VERONESE, APP. BIOCHEM. BIOTECH., vol. 11, 1985, pages 141 - 152 |
VLAK ET AL., J. GEN. V ., vol. 69, 1988, pages 765 |
W. A. HENDRICKSON; J. R. HORTON; D. M. LEMASTER, EMBO J., vol. 9, no. 5, 1990, pages 1665 - 1672 |
W. P. C. STEMMER, NATURE, vol. 370, 1994, pages 389 - 91 |
WALKER: "Protein Protocols on CD-ROM", 1998, HUMANA PRESS |
WALKER: "The Protein Protocols Handbook", 1996, HUMANA PRESS |
WALTER ET AL., J. MOL. BIOL., vol. 224, 1992, pages 1075 - 1085 |
WANG ET AL., PROC. NATL. ACAD. SCI., vol. 100, 2003, pages 56 - 61 |
WANG ET AL., SCIENCE, vol. 292, 2001, pages 498 - 500 |
WANG, L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, no. 1, 2003, pages 56 - 61 |
WANG, L. ET AL., SCIENCE, vol. 292, 2001, pages 498 - 500 |
WATSON ET AL.: "Recombinant DNA, 2nd ed.", 1992, SCIENTIFIC AMERICAN BOOKS |
WELLS ET AL.: "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites", GENE, vol. 34, 1985, pages 315 - 323 |
WELLS ET AL.: "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin", PHIL. TRANS. R. SOC. LOND. A, vol. 317, 1986, pages 415 - 423 |
WOGHIREN ET AL., BIOCONJ. CHEM., vol. 4, 1993, pages 314 |
WONG ET AL., ENZYME MICROB. TECHNOL., vol. 14, 1992, pages 866 - 874 |
WRIGHT, NATURE, vol. 321, 1986, pages 718 |
WU, Y., J. AM. CHEM. SOC., vol. 124, 2002, pages 14626 - 14630 |
Y. TANG; G. GHIRLANDA; W. A. PETKA; T. NAKAJIMA; W. F. DEGRADO; D. A. TIRRELL, ANGEW. CHEM. INT. ED. ENGL., vol. 40, no. 8, 2001, pages 1494 - 1496 |
YELTON ET AL., P . N . A . S . USA, vol. 81, 1984, pages 1470 - 74 |
YELVERTON ET AL., N . ACIDS RES., vol. 9, 1981, pages 731 |
ZALIPSKY ET AL., EUR. POLYM. J., vol. 19, 1983, pages 1177 |
ZALIPSKY, BIOCONJUGATE CHEM., vol. 6, 1995, pages 150 - 165 |
ZHANG ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 6735 - 6746 |
ZHANG, Z. ET AL., BIOCHEM., vol. 42, no. 22, 2003, pages 6735 - 6746 |
ZHANG, Z. ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 6735 - 6746 |
ZINK ET AL., BIOCHEMISTRY, vol. 33, 1994, pages 8453 |
ZINK ET AL., FEBS LETT., vol. 314, 1992, pages 435 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS IN ENZYMOL., vol. 100, 1983, pages 468 - 500 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment", NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 6500 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template", METHODS IN ENZYMOL., vol. 154, 1987, pages 329 - 350 |
Cited By (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9133457B2 (en) | 2004-05-17 | 2015-09-15 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
US8263740B2 (en) | 2004-12-22 | 2012-09-11 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8859802B2 (en) | 2004-12-22 | 2014-10-14 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8846876B2 (en) | 2004-12-22 | 2014-09-30 | Abrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8809511B2 (en) | 2004-12-22 | 2014-08-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8791231B2 (en) | 2004-12-22 | 2014-07-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US9637441B2 (en) | 2004-12-22 | 2017-05-02 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8367612B2 (en) | 2004-12-22 | 2013-02-05 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8048988B2 (en) | 2004-12-22 | 2011-11-01 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8008456B2 (en) | 2004-12-22 | 2011-08-30 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US7928163B2 (en) | 2004-12-22 | 2011-04-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8071809B2 (en) | 2005-11-08 | 2011-12-06 | Ambrx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
WO2007056448A3 (en) * | 2005-11-08 | 2009-05-14 | Ambrx Inc | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
US7888533B2 (en) | 2005-11-08 | 2011-02-15 | Ambrx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
US7468458B2 (en) | 2005-11-08 | 2008-12-23 | Amerx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
AU2006326404B2 (en) * | 2005-12-14 | 2011-11-03 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8557781B2 (en) | 2005-12-14 | 2013-10-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8865658B2 (en) | 2005-12-14 | 2014-10-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8153758B2 (en) | 2005-12-14 | 2012-04-10 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US9586988B2 (en) | 2005-12-14 | 2017-03-07 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8399614B2 (en) | 2005-12-14 | 2013-03-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8518666B2 (en) | 2006-03-03 | 2013-08-27 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
US8980581B2 (en) | 2006-03-03 | 2015-03-17 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
JP2015057404A (ja) * | 2007-03-30 | 2015-03-26 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾fgf−21ポリペプチド |
US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
JP2020018314A (ja) * | 2007-03-30 | 2020-02-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾fgf−21ポリペプチド |
US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
JP2010523084A (ja) * | 2007-03-30 | 2010-07-15 | アンブルックス,インコーポレイテッド | 修飾fgf−21ポリペプチド |
US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
JP2017212986A (ja) * | 2007-03-30 | 2017-12-07 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾fgf−21ポリペプチド |
US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
EP3225248A1 (en) | 2008-07-23 | 2017-10-04 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
US9879249B2 (en) | 2009-02-17 | 2018-01-30 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
US8952147B2 (en) | 2009-06-29 | 2015-02-10 | Sanofi | Conjugates, preparation thereof, and therapeutic use thereof |
WO2011001052A1 (fr) | 2009-06-29 | 2011-01-06 | Sanofi-Aventis | Nouveaux conjugues, leur preparation et leur application en therapeutique |
US8481042B2 (en) | 2009-08-25 | 2013-07-09 | Sanofi | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents |
WO2011023883A1 (fr) | 2009-08-25 | 2011-03-03 | Sanofi-Aventis | Conjugues de dimeres de pyrrolo [1, 4 ] benzodiazepine en tant qu' anticancereux |
WO2011039721A1 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
US9056914B2 (en) | 2010-07-26 | 2015-06-16 | Sanofi | Anticancer derivatives, preparation thereof and therapeutic use thereof |
US8945897B2 (en) | 2010-07-26 | 2015-02-03 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
WO2012014147A1 (en) | 2010-07-26 | 2012-02-02 | Sanofi | Anticancer derivatives, preparation thereof and therapeutic use thereof |
US9452222B2 (en) | 2010-08-17 | 2016-09-27 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
US11311605B2 (en) | 2010-08-17 | 2022-04-26 | Ambrx, Inc. | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides |
US11439710B2 (en) | 2010-08-17 | 2022-09-13 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
US10751391B2 (en) | 2010-08-17 | 2020-08-25 | Ambrx, Inc. | Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid |
US10702588B2 (en) | 2010-08-17 | 2020-07-07 | Ambrx, Inc. | Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain |
US11786578B2 (en) | 2010-08-17 | 2023-10-17 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
EP4302783A2 (en) | 2010-08-17 | 2024-01-10 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
US10183998B2 (en) | 2011-01-14 | 2019-01-22 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
JP2013199466A (ja) * | 2012-02-24 | 2013-10-03 | Fujifilm Corp | リコピン含有組成物 |
EP2819702A4 (en) * | 2012-02-29 | 2015-05-20 | Ambrx Inc | NOVEL PRODRUGS WITH MOLECULE COMPOSITIONS AND ITS USES |
WO2013185117A1 (en) * | 2012-06-07 | 2013-12-12 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
AU2013270686B2 (en) * | 2012-06-07 | 2016-11-10 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
US10800856B2 (en) | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
EP3536700A1 (en) * | 2012-06-07 | 2019-09-11 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
US11958909B2 (en) | 2012-06-08 | 2024-04-16 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US10669347B2 (en) | 2012-06-08 | 2020-06-02 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US11459392B2 (en) | 2012-06-19 | 2022-10-04 | Ambrx, Inc. | Anti-CD70 antibody drug conjugates |
US10208123B2 (en) | 2012-06-19 | 2019-02-19 | Ambrx, Inc. | Anti-CD70 antibody drug conjugates |
WO2013192360A1 (en) * | 2012-06-19 | 2013-12-27 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
EP3488870A1 (en) * | 2012-06-19 | 2019-05-29 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
US10501558B2 (en) | 2012-06-26 | 2019-12-10 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014004639A1 (en) * | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
EP3135690A1 (en) * | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
US10112900B2 (en) | 2012-08-31 | 2018-10-30 | Sutro Biopharma, Inc. | Modified amino acids |
US9682934B2 (en) | 2012-08-31 | 2017-06-20 | Sutro Biopharma, Inc. | Modified amino acids |
US11548852B2 (en) | 2012-08-31 | 2023-01-10 | Sutro Biopharma, Inc. | Modified amino acids |
US9994527B2 (en) | 2012-08-31 | 2018-06-12 | Sutro Biopharma, Inc. | Modified amino acids |
US10730837B2 (en) | 2012-08-31 | 2020-08-04 | Sutro Biopharma, Inc. | Modified amino acids |
US10960082B2 (en) | 2013-01-23 | 2021-03-30 | Newbio Therapeutics, Inc. | Tridentate connexon and use thereof |
WO2014114207A1 (zh) | 2013-01-23 | 2014-07-31 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
US11344626B2 (en) | 2013-07-10 | 2022-05-31 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2016065326A2 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
EP3412302A1 (en) | 2014-10-24 | 2018-12-12 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
EP3909596A1 (en) | 2014-10-24 | 2021-11-17 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
US11125659B2 (en) | 2015-03-31 | 2021-09-21 | Eiken Kagaku Kabushiki Kaisha | Preservative solution for heme protein, and method for stabilizing heme protein |
EP3279660A4 (en) * | 2015-03-31 | 2018-09-05 | Eiken Kagaku Kabushiki Kaisha | Preservative solution for heme protein, and method for stabilizing heme protein |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US10293055B2 (en) | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10328157B2 (en) | 2015-07-15 | 2019-06-25 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10232051B2 (en) | 2015-07-15 | 2019-03-19 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US11708413B2 (en) | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
US11788066B2 (en) | 2016-04-26 | 2023-10-17 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
EP3888691A1 (en) | 2016-11-14 | 2021-10-06 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
WO2019185706A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
WO2019185705A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
WO2021000067A1 (zh) | 2019-06-29 | 2021-01-07 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
US11879001B2 (en) | 2020-06-03 | 2024-01-23 | Ascendis Pharma Oncology Division A/S | Conjugate comprising an IL-2 moiety |
WO2021245130A1 (en) | 2020-06-03 | 2021-12-09 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
WO2023281479A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
WO2023281481A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics | Antibody conjugates and manufacture thereof |
WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
WO2023281483A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified tnf-antibodies and uses thereof |
WO2023161857A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023161854A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9637441B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
AU2013205030B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
AU2012202615B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580044328.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 183346 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005319125 Country of ref document: AU Ref document number: 555308 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2590590 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005319125 Country of ref document: AU Date of ref document: 20051221 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/007590 Country of ref document: MX Ref document number: 2007548475 Country of ref document: JP Ref document number: 2687/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 0713066 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20051221 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0713066.9 Country of ref document: GB Ref document number: 2005855215 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077016540 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0516385 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 220740 Country of ref document: IL |